Cited by 17COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19

Beyond dexamethasone, emerging immuno‐thrombotic therapies for COVID‐19

Open access
Jensen, Melanie Peta, George, Marc, Gilroy, Derek, Sofat, Reecha·2021·British Journal of Clinical Pharmacology

Abstract

Host immunity is required to clear SARS‐CoV‐2, and inability to clear the virus because of host or pathogen factors renders those infected at risk of poor outcomes. Estimates of those who are able to clear the virus with asymptomatic or paucisymptomatic COVID‐19 remain unclear, and dependent on widespread testing. However, evidence is emerging that in severe cases, pathological mechanisms of hyperinflammation and coagulopathy ensue, the former supported by results from the RECOVERY trial demonstrating a reduction in mortality with dexamethasone in advanced COVID‐19. It remains unclear whether these pathogenic pathways are secondary to a failure to clear the virus because of maladaptive immune responses or if these are sequential COVID‐19 defining illnesses. Understanding the pathophysiological mechanisms underpinning these cascades is essential to formulating rationale therapeutic approaches beyond the use of dexamethasone. Here, we review the pathophysiology thought to underlie COVID‐19 with clinical correlates and the current therapeutic approaches being investigated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.14540

Cites

146 of 146 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 3

  1. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID- 19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020;49:E009.
  2. Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, a risk factor of severe COVID-19 patients. medRxiv 2020: 2020.03.24. 20040162.
  3. Takahashi T, Wong P, Ellingson M, et al. Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes. medRxiv 2020: 2020.06.06.20123414.

Cited by

Sorted by citations

Authors
Jensen, M. P., George, M., Gilroy, D., & Sofat, R.
Affiliations
  • Royal London Hospital (GB)
  • University College London (GB)
Corresponding author
Sofat, Reecha
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2020-10-14
Volume
87
Issue
3
Pages
845-857
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W3082169420
Cited by
17
References
146
Citations by year
2025: 1 · 2022: 11 · 2021: 4 · 2020: 1
FWCI
0.19
Type
journal article
Language
en
Open access
Locations
  • British Journal of Clinical Pharmacology (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
National Institute for Health and Care Research (ACF-2020-21-012)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
Keywords
COVID-19 pandemic, SARS-CoV-2, dexamethasone, hyperinflammation, coagulopathy, host immunity, pathophysiology, severe COVID-19, anticoagulation, immunomodulatory therapy
MeSH terms
COVID-19, COVID-19 Drug Treatment, Antiviral Agents, Dexamethasone, Fibrinolytic Agents, Humans, Immunologic Factors, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review